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ABSTRACT
In the nineteenth century, it was recognised that 
acute attacks of chronic bronchitis were harmful. 140 
years later, it is clearer than ever that exacerbations 
of chronic obstructive pulmonary disease (ECOPD) are 
important events. They are associated with significant 
mortality, morbidity, a reduced quality of life and an 
increasing reliance on social care. ECOPD are common 
and are increasing in prevalence. Exacerbations beget 
exacerbations, with up to a quarter of in-patient episodes 
ending with readmission to hospital within 30 days. The 
healthcare costs are immense. Yet despite this, the tools 
available to diagnose and treat ECOPD are essentially 
unchanged, with the last new intervention (non-invasive 
ventilation) introduced over 25 years ago.
An ECOPD is ’an acute worsening of respiratory symptoms 
that results in additional therapy’. This symptom and 
healthcare utility-based definition does not describe 
pathology and is unable to differentiate from other causes 
of an acute deterioration in breathlessness with or without 
a cough and sputum. There is limited understanding of 
the host immune response during an acute event and no 
reliable and readily available means to identify aetiology or 
direct treatment at the point of care (POC). Corticosteroids, 
short acting bronchodilators with or without antibiotics 
have been the mainstay of treatment for over 30 years. This 
is in stark contrast to many other acute presentations of 
chronic illness, where specific biomarkers and mechanistic 
understanding has revolutionised care pathways. So why 
has progress been so slow in ECOPD? This review examines 
the history of diagnosing and treating ECOPD. It suggests 
that to move forward, there needs to be an acceptance 
that not all exacerbations are alike (just as not all COPD is 
alike) and that clinical presentation alone cannot identify 
aetiology or stratify treatment.
‘Next to avoiding a fatal issue, our efforts 
must be directed to prevent the case going on 
to chronic bronchitis, especially in those who 
have had previous attacks’.
R Douglas Powell, London (1878)
InTRoduCTIon
An exacerbation of chronic obstructive pulmonary 
disease (COPD) is defined as ‘an acute worsening 
of respiratory symptoms that results in additional 
therapy’.1 The word exacerbation has a Latin 
root; stemming from the verb exacerbare meaning 
‘to provoke to anger’ and the Oxford English 
Dictionary defines an exacerbation as ‘the process 
of making a problem, bad situation, or negative 
feeling worse’.2 This accurately reflects the nega-
tive impact COPD exacerbations (ECOPD) have on 
patient quality of life,3 lung function decline4 and 
mortality.5 In the UK, national audit data highlight 
the high mortality and readmission rates (and thus 
healthcare costs) associated with ECOPD.6 Exacer-
bations impact on patients’ quality of life3 and even 
a single exacerbation is associated with an increase 
in mean annual forced expiratory volume (FEV1) 
decline.7 The early identification, provision of 
appropriate treatment and subsequent prevention 
(or ideally, primary prevention) of exacerbations 
has to be a central strategy for COPD care.
We use clinical symptoms to diagnose an exac-
erbation of COPD, based on the triad of increased 
breathlessness, increased sputum volume and/ or 
increased sputum purulence. These criteria are 
essentially unchanged over the last 180 years,8 
finessed with clinical investigations such as a chest 
radiograph, arterial blood gas, ECG, a full blood 
count and sputum culture (all available since 
1872–1924).9–13 In stark terms, our diagnostic 
approach to COPD exacerbations has not funda-
mentally changed for almost 100 years. We have 
no COPD-specific biomarkers and the diagnosis is 
often one of exclusion. This is in contrast to many 
other acute presentations of chronic diseases, such 
as a myocardial infarction (MI) in ischaemic heart 
disease, where specific and sensitive diagnostic 
toolkits including biomarkers, imaging and inter-
ventions have revolutionised care pathways and 
patient outcomes. Such disparity in advancement 
raises the question of why COPD is so far behind 
other common, debilitating and progressive chronic 
diseases which are associated with acute flares of 
symptoms. Why do we not have a better diagnostic 
and treatment toolkit for ECOPD? Perhaps to move 
forward, we need to examine the past.
TRIggeRS of exACeRBATIonS And ouR 
ABIlITy To dIffeRenTIATe BeTween Them 
ClInICAlly
In 1878, Douglas Powell identified cold weather, 
upper respiratory tract infections and pollution as 
an important causes of (acute) bronchitis, observing 
that ‘dusty employments…dusty winds (and) irri-
tating fogs’ bring on typical attacks.14 Today, the 
most important listed triggers of exacerbations of 
COPD include viral and/ or bacterial tracheobron-
chial infection15 and inhalation of environmental 
irritants.
In a study of 64 hospitalised (and thus severe) 
exacerbations of COPD, bacteria or viruses were 
identified in 78% using quantitative culture 
and PCR.16 Bacteria were present in 55% of 
patients, most commonly Haemophilus influ-
enzae, Streptococcus pneumoniae, Moraxella 
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figure 1 The variability of inflammation in sputum in one patient with 
COPD. A spontaneous sputum sample was collected over 4 hours post 
waking and following mouth rinsing procedures daily for 5 days (visits 
1–5), and then twice weekly for 3 further weeks (visits 6,7; 8,9; 10,11) 
in a patient with moderate severity COPD in the stable state who had 
been an ex-smoker for 17 years. A differential cell count was performed 
and cytokines were measured in sputum sol phase. Each marker is the 
concentration of that mediator on the visit day. Neutrophil (PMN) 106/
ml (red circles), myeloperoxidase (MPO) mg/ml (green square); TNFα 
pM (cerise triangle): IL8 nM (cyan triangle); LTB4 nM (black diamond). 
adapted from Sapey et al.29 COPD,chronic obstructive pulmonary 
disease; TNF, tumour necrosis factor.
catarrhalis; Staphylococcus aureus and Pseudomonas aeruginosa, 
in descending order of prevalence. Viruses were found in 48%, 
with rhinoviruses, influenza viruses, respiratory syncytial viruses, 
parainfluenza viruses and coronaviruses most commonly identi-
fied, again in descending order of prevalence.16 Viral infections 
are important in COPD, associated with frequent exacerbations, 
a higher total symptom burden at presentation and a longer 
period before symptom recovery,17 perhaps reflecting the lack 
of specific therapies available. Coinfection (bacterial and viral) is 
common (seen in 25% of severe exacerbations), associated with 
increased lung and systemic inflammation, longer hospitalisa-
tion and more severe lung disease.16 The role of air quality is of 
increasing interest. Short-term exposure to major air pollutants 
(trioxygen (O3), carbon monoxide, nitrogen dioxide, sulphur 
dioxide, particulate matter (PM)10 and PM2.5) is associated with 
respiratory risk but a recent systematic review concluded that 
these pollutants were also associated with risk of exacerbation.18 
Other identified triggers and/or risk factors for exacerbation 
include discontinuation and poor adherence with medications,19 
poor nutritional and lower socioeconomic status20 and dynamic 
hyperinflation.21 These causative triggers and predisposing 
factors have been consistently identified across the literature, 
but studies also highlight alternative pathologies which might 
account for symptoms, including thromboembolic disease and 
MI (identified in 16%22 and 8%23 of suspected COPD exacerba-
tions, respectively), suggesting comorbidity is important.
The treatment of exacerbations has remained short-acting 
bronchodilators and corticosteroids with or without antibi-
otics for 30 years, almost irrespective of the underlying cause. 
However, with global concerns about antibiotic use and an 
increasing number of clinical trials of new or repurposed ther-
apeutics given at the time of exacerbation, identifying the 
exacerbation trigger has never felt more relevant. Can clinical 
evaluation alone help identify the cause?
From the late 1990s onwards, a body of evidence supported 
the concept that the presence of purulent sputum at exacerbation 
presentation was indicative of a bacterial exacerbation (eg 
Stockley et al,24) and this has been used ever since as a potential 
biomarker for bacterial infections. However, there are concerns 
about the ability of patients to self-report sputum colour without 
training or a colour chart to refer to Daniels et al25 and in some 
studies, sputum colour could not differentiate between a viral or 
bacterial aetiology.16 A landmark study in 201126 suggested that 
exacerbations could be stratified using inflammatory profile. 
Here, 55% of exacerbations were associated with bacteria, 29% 
with a virus, most commonly rhinovirus, 28% with a significant 
sputum eosinophilia and 14% with no significant inflammation 
(termed pauci-inflammatory). Of note, these groupings did not 
reflect differences in symptom burden, clinical presentation or 
sputum colour, which could not differentiate between causes,26 
meaning clinicians could not predict what the cause or inflam-
matory profile of the exacerbation was using standard clinical 
evaluation alone. This has important but perhaps predictable 
implications for clinical practice. Moving forward, as with other 
acute presentations of chronic disease, we should not rely on 
clinical symptoms, signs or non-specific investigations to direct 
a stratified approach to exacerbation treatment. Given COPD 
is an inflammatory disease, the immune response may provide 
aetiological insight.
The hoST ReSponSe To exACeRBATIonS
In 1958 Engel hypothesised that the structural lung damage 
described in chronic bronchitis and emphysema might be caused 
by repeated infections, with multiple acute insults leading to 
long-term lung damage.27 In 1968, Morgan suggested that there 
were differences in the acute and chronic inflammation seen in 
the bronchial tree and surmised that these differences may influ-
ence patient outcome and require different treatments.28 Fifty 
years on from this observation, how far has our understanding 
of the inflammatory basis of acute exacerbations of COPD 
progressed?
There is a substantial and convincing body of evidence that 
airway inflammation is prevalent in stable COPD and is funda-
mental to its pathogenesis with studies suggesting relationships 
with disease severity and inflammatory burden.29 However, 
pulmonary inflammation varies greatly between individuals and 
within individuals with COPD even when clinically stable30 and 
this heterogeneity has proven challenging in biomarker evalua-
tion or inflammation-targeted therapeutic intervention.
Figure 1 provides an example of the variability of the inflam-
matory profile of spontaneous sputum inflammation day to day 
in one patient with COPD. As shown, although some media-
tors share a common pattern of change (if one mediator is up, 
others are up and vice versa), not all do (eg, on visit 2, tumour 
necrosis factor (TNF)α has increased, but leukotriene B4 (LTB4) 
and interleukin-8 (IL8) have decreased) and this suggests that 
the variability in mediators does not only reflect dilution of the 
sample, but true variability in inflammatory pattern.
There appears to be a further amplification of inflammation 
during exacerbation in many (but not all) patients. Once an insult 
(bacterial, viral or environmental) sufficiently activates the resi-
dent immune cells of the airways, it appears to trigger a cascade 
of inflammatory mediators.31 This in turn recruits a wave of 
activated immune cells to the airways, which are predominantly 
neutrophils16 but also include eosinophils, monocytes and CD8 
+T cells3233 and these cells have the potential to cause signif-
icant disruption and damage when they enter tissue en masse. 
For example, activated neutrophils release proteinases during 
migration through complex tissues, degranulation, frustrated 
2 Sapey E, et al. Thorax 2019;0:1–8. doi:10.1136/thoraxjnl-2018-213035
 o
n
 4 July 2019 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2018-213035 on 3 July 2019. Downloaded from 
State of the art review
figure 2 The inflammatory cascade in COPD exacerbations. A 
summary of inflammatory and cellular interactions linking exacerbations 
to the chronic inflammation of COPD. 1. The precipitating event (which 
could be a bacterial or viral infection or an environmental trigger causes 
inflammation of the airway epithelium). 2. Activation of the resident 
immune cells including macrophages and T cells. 3. Where local host 
defences are overwhelmed, non-resident immune cells, predominantly 
neutrophils, but also T cells, B-cells and eosinophils are recruited into the 
lung tissue, following chemokines secreted by epithelial and endothelial 
cells and resident immune cells. Fibroblasts may be activated by growth 
factor releases from macrophages and epithelial cells. 4. Recruited and 
resident immune cells are able to release cytotoxic granular contents, 
reactive oxygen species and proteinases into the tissue and these have 
been causally associated with the development of mucus secretion, but 
also emphysema and small airways remodelling, leading to progression 
of the underlying COPD.
phagocytosis and Neutrophil extracellular traps (NET) forma-
tion.34 The concentration of proteinases initially far exceed 
and thus overwhelm their inhibitors leading to degradation of 
structural lung proteins including elastin and collagen causing 
bystander tissue damage and cleavage of enzymes, cytokines, 
receptors and opsonins including components of the comple-
ment cascade and immunoglobulins.35 36 While tissue damage is 
heightened in exacerbations of COPD, tissue repair is blunted, 
effecting the structural integrity of the airways.37 This inflamma-
tory cascade also results in systemic inflammation, with increases 
in acute phase proteins such as fibrinogen and C reactive protein 
(CRP). Relationships have been described between the degree 
of pulmonary and systemic inflammation in some studies,38 a 
potential link between the multimorbid diseases associated with 
COPD and COPD exacerbations (see later). These processes are 
illustrated in figure 2.
COPD severity (definable by a number of measures, but 
commonly by FEV in one second (FEV1) at one timepoint) is not 
synonymous with COPD activity (the trajectory of lung function 
decline or exacerbation frequency). Some patients have mild 
COPD by FEV1 which is rapidly progressing or with frequent 
exacerbations and vice versa. While hypothetically attractive, 
studies have not consistently linked disease activity (such as 
exacerbation frequency) to the presence of increased airways 
inflammation in the stable state.39 However, the presence of 
potentially pathogenic bacteria on sputum culture is associated 
with exacerbation frequency40 and there is a clear relationship 
with bacteria and inflammation39 which supports the concept 
of inflammatory burden increasing the susceptibility to exacer-
bations. It is likely that some studies have been underpowered 
to assess differences in inflammation or have failed to include 
patients with high exacerbation frequencies, which is under-
standable given the challenges of recruiting these unstable 
patients to research studies.
There is an association between inflammation and exacer-
bation outcome. Symptom resolution corresponds to abating 
inflammation and continuation of symptoms or recurrence 
of exacerbation corresponds to sustained inflammation,41 
suggesting a causal relationship between inflammatory load and 
host experience. While it is attractive to assume that all exacer-
bations of a certain aetiology might share the same inflamma-
tory profile and burden, the complexity of host, environment 
and exacerbation trigger interactions within COPD are likely to 
produce patterns with greater subtlety than that. However, just 
as with stable COPD,42 within COPD exacerbations there might 
be phenotypes or ‘treatable traits’ which could help focus ther-
apeutic choices.
Immune cell function might provide mechanistic insight. It has 
been proposed that some frequently exacerbating COPD patients 
might experience a ‘triple innate immune system hit’ which 
could increase their susceptibility to bacterial exacerbations. 
First, the frequent exacerbator phenotype has been associated 
with a reduced ability of airway macrophages to phagocytose 
bacteria.43 Theoretically, this would lead to increased neutro-
phil recruitment and in this group neutrophilic inflammation is 
commonly described.31 Second, studies suggest the accuracy of 
neutrophil targeting is impaired in COPD and associated with 
heightened bystander tissue damage.44 Third, airway macro-
phages and monocytes from the frequent exacerbator phenotype 
are less able to clear dead and dying neutrophils (and eosino-
phils45 via efferocytosis,46 resulting in cell necrosis and localised 
inflammation and tissue damage). Neutrophilic inflammation is 
corticosteroid resistant in COPD but promisingly, studies have 
identified potential therapeutic targets to improve impaired 
cellular functions. NrF2 activators increase macrophage phago-
cytosis46 and PI3K inhibitors have been shown to increase 
neutrophil migratory accuracy in vitro as well as reducing 
inflammation47 with PI3K inhibitors under assessment in early 
phase studies as a potential therapy during COPD exacerbations.
Due to advancements initially in asthma care, trials of ther-
apies in those COPD patients with an eosinophil signal are 
well underway (with 70 studies currently listed on the  clini-
caltrials. gov website).48 Results to date suggest that this trait is 
associated with a good treatment response to oral steroids at 
exacerbation49 and inhaled steroids in the stable state,50 with 
studies of specific antieosinophil therapies (including mepoli-
zumab) showing promise in selected patient groups.51 Further-
more, studies of community-treated exacerbation suggest that 
there is no advantage in treating adults without an eosinophil 
signal with oral prednisolone, as this provides no symptomatic 
benefit and an increase risk of harm.49 In hospitalised ECOPD, 
studies suggest that oral corticosteroids and shorter courses 
appear adequate, with no benefit using high-dose intravenous 
therapy.52 Excessive use of oral corticosteroids is associated 
with harm, which is especially clear in studies of patients on 
long-term maintenance53 but also potentially raises concerns 
about uncontrolled and/or unsupported use of ‘rescue packs’. 
Of note, a recent Cochrane review concluded that there was 
no evidence of benefit from self-management interventions 
(including rescue packs) to reduce all‐cause hospital admis-
sion, all‐cause hospitalisation days, emergency department 
visits, general practitioner visits, dyspnoea scores, the number 
of COPD exacerbations or all‐cause mortality54 although more 
research was needed. However, the provision of a rescue pack 
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for patients with exacerbations remains a recommendation 
from the National Institute for Health and Care Excellence in 
the revised guideline published in December 2018 (based on 
expert opinion).55
These studies begin to highlight that there are different types 
of COPD exacerbations, with different responses to treatment 
and that a ‘one size fits all’ approach for both treatment and 
prevention is overly simplistic. To further advance inflamma-
tion-based treatments, a toolkit is needed to match exacerbation 
aetiology with host response and therefore treatment. In other 
words, we need to phenotype exacerbations.
phenoTypIng exACeRBATIonS
The value of phenotyping exacerbations of COPD is to derive 
patterns for treatment response or to enhance our understanding 
of underlying mechanisms. A frequently used, yet rudimentary 
classification of an exacerbation phenotype is the categorisation 
as ‘infective’ or ‘non-infective’ exacerbations of COPD.56 This is 
commonly used to direct treatment with antibiotics and systemic 
corticosteroids, respectively57 but does not inform underlying 
mechanisms, likely treatment response or if the exacerbation 
severity and outcomes are the same. Recent advances which 
exploit developments in biomarker identification, mediator 
discovery and molecular diagnostics,58 59 for example in micro-
bial detection, have furthered our understanding of the exacer-
bation event.
Biological exacerbation phenotypes: systemic biomarkers
There has been great interest in studying systemic plasma samples 
in COPD to provide insight into the pathogenesis of exacerba-
tions. One such study included 90 exacerbating patients (unse-
lected, of any aetiology), assessing 36 preselected inflammatory 
mediators. Of these, CRP, interleukin-6, myeloid-progenitor 
inhibitory factor 1, pulmonary and activation-regulated chemo-
kine, adiponectin and soluble intracellular adhesion molecule-1 
were significantly elevated at the exacerbation event. However, 
no plasma mediator alone provided a robust predictive tool for 
diagnosing an exacerbation event. CRP combined with a major 
symptom (dyspnoea, sputum purulence or sputum volume) 
improved diagnostic accuracy but no mediator/symptom combi-
nation predicted clinical severity or recovery.60 This result may 
reflect that the study included ‘all comers’ with an exacerbation 
(all aetiologies) and therefore might have been underpowered 
to find predictive biomarkers if the biomarkers varied by aeti-
ology or host response. To address this, further studies utilised 
differing approaches to identify phenotypes of exacerbations.
Biological exacerbation phenotypes: human rhinovirus 
biomarkers
The first attempts to investigate biomarkers in virus-associated 
exacerbations as a specific phenotype were made from the East 
London Cohort.61 In this study, human rhinovirus (HRV) infec-
tion was examined in healthy controls and COPD patients at 
stable state and during exacerbation.61 Baseline CXCL10 (inter-
feron gamma inducible protein 10) was higher in COPD than 
controls, but at exacerbation, there was an increase in serum 
CXCL10 in HRV positive exacerbations, correlating with sputum 
HRV virus load, and no increase in HRV negative exacerbations. 
A combination of ‘cold’ symptoms and serum CXCL10 at exac-
erbation was associated with a ROC of 0.82 in predicting an 
HRV-associated exacerbation of COPD.
Biological exacerbation phenotypes: independent biological 
clusters
The studies described so far tested preformed hypotheses to 
identify associations between inflammatory profiles and exac-
erbation. In the first study of its kind, the BEAT-COPD study 
employed cluster analysis using mediators sampled from the 
airways to determine biologically distinct exacerbation groups.62 
Four biological exacerbation phenotypes were described, 
mapping on to inflammation, independent of each other but 
clinically indistinguishable. Sputum interleukin 1β (IL1β) was 
found to be most sensitive for bacteria-associated exacerbations 
(proinflammatory cluster, Receiver Operating Characteristic 
curve (ROC) 0.89), serum CXCL10 was (again) most sensitive 
for virus-associated exacerbations (Th1 cluster, ROC 0.76) and 
peripheral blood eosinophils (Th2 cluster, ROC 0.85) was the 
most sensitive for sputum eosinophilic-associated exacerbations. 
An independent validation cohort of 89 subjects confirmed that 
sputum IL1β, serum CXCL10 and peripheral blood eosinophils 
continued to show predictive power for identifying phenotypes, 
with ROC of 0.73 (0.61–0.85), 0.65 (0.52–0.78) and 0.95 
(0.87–1.00), respectively.
These studies highlight four potential exacerbation pheno-
types which might provide robust treatment pathways in time. 1. 
Bacterial in origin, IL-1β as a biomarker, neutrophilic inflamma-
tion. 2. Viral in origin, with CXCL10 as a biomarker. 3. Eosino-
phillic in origin and as a biomarker. 4 Pauci-inflammatory. These 
appear to be biologically different even when clinically indistin-
guishable. However, while our understanding of each of these 
phenotypes needs to be improved, we understand very little at 
all about the so-called pauci-inflammatory exacerbation. Indeed, 
it is unclear whether this represents COPD at all or the acute 
presentation of a related comorbidity which may also cause or 
exacerbate breathlessness and a cough.
ComoRBIdITIeS And Copd exACeRBATIonS
The recognition and gravitas of comorbidities in COPD has built 
over the last decade or more. Whether the presence of comor-
bidities is based on self-report63 or systematically sought,64 they 
are common and affect mortality.65 Exacerbations represent a 
period with multiple insults to both the lung and systemically. 
Such insults include the aetiological factor itself (pathogen or 
environmental), lung physiological changes and additional 
work of breathing, hypoxia, periods of inactivity (which can 
effectively be prolonged periods of ‘bed rest’ during an in-pa-
tient admission), with a study suggesting that an acute medical 
admission is associated with a median step count of 626 per 
day (IQR 266–1403),66 dehydration, malnutrition, the ther-
apies prescribed and their side effects (eg, oral corticosteroids 
and hyperglycaemia and antibiotics and gastrointestinal distur-
bance) and then the sequelae of these factors including systemic 
inflammation, hypo and hypernatraemia/kalaemia and altered 
sympathetic drive. Figure 3 summarises the complex relation-
ships between comorbidity and exacerbations in COPD. There 
is a significant and complex interplay between the exacerbation 
and the comorbid condition including the impact of comorbidi-
ties on the exacerbation itself; how an exacerbation contributes 
to comorbid disease; the prognostic role of comorbid disease 
and the subclinical presentation of a comorbid condition at the 
time of an exacerbation. Cardiovascular disease highlights the 
interplay and is the most studied comorbidity in this context.
Patients presenting to hospital with a COPD exacerbation 
have a host of comorbid conditions67 and the presence of a 
comorbid condition and the systemic manifestation of that 
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figure 3 Comorbidity and COPD exacerbations. There are many 
stressors during COPD exacerbations which can predispose to or 
exacerbate comorbidities and the multimorbidity patients experience. 
This figure is a schematic of some of these factors, but is not exhaustive 
and each stressor can influence the other, irrespective of placement 
in the figure. Stressor include the direct effects of infection and 
inflammation, dyshomeostasis including hypo and hypernatraemia, 
kalaemia and glycaemia, hypoxia and hypercapania. Organ dysfunction 
is common, especially of cardiac and renal origin. Patients are placed 
on short courses of oral corticosteroids and physical activity is reduced 
(and can equate to bed rest in some patients), both contributing to 
sarcopenia and osteopenia. COPD, chronic obstructive pulmonary 
disease.
comorbidity increases the duration of an exacerbation. Coex-
istent ischaemic heart disease leads to far greater number of 
symptomdays per year,68 while an increased blood glucose in 
hospitalised patients leads to a longer stay and is associated with 
a higher risk of death.69 MI is more likely in the period following 
presentation with an exacerbation70–72 and there is evidence of 
increase platelet aggregation, increased arterial stiffness as well 
as myocardial injury as evidenced by cardiac biomarkers at 
the time of a COPD exacerbation.73 74 The fact that comorbid 
disease may present subclinically at the time of the exacerbation 
is also important to consider, be it as a differential or as a further 
contributing factor to the symptoms and challenges of managing 
the condition. In a prospective case series, one in 12 patients 
presenting to hospital with an exacerbation of COPD had 
criteria that would meet diagnosis of a MI.23 Impaired cognitive 
function is evident, if assessed, in a large proportion of patients 
at the time of discharge from a hospitalised exacerbation, with 
no evidence of recovery 3 months later.75
Prognostically, comorbidities present a greater risk of hospi-
talisation,76 particularly in the presence of lower lung function, 
as well as increased all-cause readmissions related to multi-
morbidity and older age.77 In the ECLIPSE study (Evalua-
tion of COPD Longitudinally to Identify Predictive Surrogate 
End-points), the best predictor of exacerbations was a former 
history of them. In addition, however, a history of reflux and 
heartburn was a further independent factor.78 The presence of 
acute kidney injury79 and lower limb muscle cross-sectional area 
at the time of exacerbation requiring hospitalisation are both 
prognostic of death.80 The prognostic COPD exacerbation 
score such as the validated DECAF score81 (“Dyspnoea, Eosin-
openia, Consilidation, Acidaemia and atrial Fibrillation” score 
predicting in-patient mortality) and the PEARL score (“Previous 
admissions, eMRCD score, Age, Right-sided heart failure and 
Left sided heart failure” score predicting 90-day readmission 
and mortality)82 include cardiac comorbidity in their calcula-
tions. Patients deemed as frequent exacerbators are more likely 
to be depressed83 84 or have coexistent cardiovascular disease or 
osteoporosis.84
It is unclear if some events labelled exacerbations are actually 
a presentation of a comorbid condition (and studies suggest that 
clinicians are less likely to diagnose MI or Pulmonary Embolus 
(PE) if there is a concomitant diagnosis of COPD,85 86) perhaps 
the so-called pauci-inflammatory exacerbations, or whether the 
comorbidity is exacerbating the COPD.
There remains a role for more timely identification of comorbid 
disease and addressing the contributing factors. The role of 
systematic identification of certain comorbidities and of preven-
tative strategies, both pharmacologically and lifestyle-based are 
topics for ongoing discussion and research.87 88 In the meantime, 
opportunity exists to ensure optimal treatment for those with 
identified comorbid disease, such as ensuring beta-blockers are 
prescribed in those who meet the criteria or that hyperglycaemia 
or hyperlipidaemia are adequately addressed.89
exACeRBATIon TReATmenT
Despite a greater understanding of the biology and complexity 
of COPD exacerbations, this has not (yet) translated into novel 
therapies to treat exacerbations. There has been no new inter-
vention to treat COPD exacerbations since the widespread 
adoption of non-invasive ventilation to treat exacerbations 
with hypercapnoeic respiratory failure in the early 1990s. 
From the first introduction of guidelines such as GOLD 
in 1997, the therapy for an exacerbation is unchanged. As 
described below, despite being commonly used, there remain 
significant research knowledge gaps in determining which 
exacerbations do and do not require treatments with antibi-
otics and corticosteroids.
Systemic corticosteroids were first used in rheumatolog-
ical disease during the late 1940s. Despite evidence in the 
late 1980s that many hospitalised patients were being treated 
with systemic corticosteroids,90 it was only at the turn of 
the millennium that small randomised clinical trails (RCTs) 
first documented clinical efficacy, suggesting benefit on lung 
function and outcomes such as length of hospital stay.91 Around 
the same time, the first small outpatient trials of steroids at exac-
erbation reported,92 with modest benefits confirmed in a larger 
2003 RCT.93 Later it was defined that short course (5 days) treat-
ment was as effective as longer 14 day courses, and without the 
need to taper dose.94 With a greater emphasis on exacerbation 
phenotyping, more recent studies have documented the ability to 
safely withhold steroids in exacerbations without an eosinophil 
signal.49 However, the practicality of achieving this at point-of-
care, and the optimal blood eosinophil cut-off to guide steroid 
therapy remain to be determined, and there are ongoing trials 
in the area. Given the toxicity associated with repeated courses 
of corticosteroids, the need for effective novel anti-inflamma-
tory agents is also great. Disappointingly, there is no evidence of 
benefit with the anti-TNF agent entanercept95 or roflumilast,96 
for example.
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Table 1 Interventions that have been demonstrated to reduce the 
risk of exacerbation and/or hospitalisation in patients with COPD, 
alone or in combination106
non-pharmacological pharmocological
Influenza vaccination Inhaled corticosteroid
Pneumococcal vaccination Long acting beta agonists
Pulmonary rehabilitation Long acting antimuscarinics
Volume reduction interventions Long-term macrolide antibiotics
Domiciliary non-invasive ventilation Mucolytic-antioxidants
 PDE4 inhibitors
 Anti-IL5
Not all interventions are effective in all patients and a personalised approach is 
mandatory.
COPD, chronic obstructive pulmonary disease.
Anthonisen’s 1987 RCT demonstrated the superiority of anti-
biotics over placebo in exacerbations presenting with at least 
two of the three cardinal symptoms of increased breathlessness, 
sputum volume and sputum purulence.97 Importantly, this had 
been conducted in patients with COPD, rather than just those 
with chronic bronchitis. However, the placebo response rate 
was high, likely reflecting viral pathogens as a common cause 
of exacerbation, and more recent studies have not shown a 
benefit of antibiotics in other outcomes such as prolonging the 
time to next exacerbation.98 Biomarkers such as sputum colour 
and procalcitonin99 have been suggested as strategies to better 
guide antibiotic therapy, but there remains unmet need to better 
define which exacerbations do and do not benefit from antibi-
otic therapy. It is also notable that there are no effective inter-
ventions to treat (or prevent) rhinovirus infections, thought to 
be the single the most common cause of a COPD exacerbation.
Salbutamol has been available since the late 1960s, with ipra-
tropium following in the 1970s. These replaced the non-selective 
β adrenoreceptor agonist isoprenaline. There are no good data 
on long-acting bronchodilator drugs at the time of exacerbation.
The 1980s audit referred to above90 highlighted the wide-
spread use of theophyllines (in 48% of patients), and use of 
respiratory stimulants such as doxapram in the management 
of hospitalised exacerbations. Use of theophylline has reduced, 
while respiratory stimulants have been replaced by non-invasive 
ventilation for the management of hypercapnoeic respiratory 
failure in the respiratory ward environment, following initial 
studies in the early 1990s100.
Models of care have changed, with the recognition that 
earlier access to treatment for exacerbations can be associated 
with faster recovery and reduced risk of hospital admission.101 
However, the risks and benefits of patient-held rescue packs 
remain to be definitely established.54
Research to develop new interventions at exacerbation of 
COPD is hampered by robust outcome measures to assess exac-
erbation recovery. Changes in lung function are not patient 
centred, and changes in symptoms scores not validated. ‘Clinical 
recovery’ and ‘treatment failure’ are subjective constructs, while 
studies have also examined effects of exacerbation treatment on 
the time to the next event given that exacerbations cluster in 
time, with a high-risk period for a second event in the period 
following recovery from a first.102
We have at least made progress in prevention of exacerbations, 
though even when used optimally there seems to be a ceiling of 
reduction at around 25%. Effective interventions (outlined in 
table 1), alone and in combination, include non-pharmacological 
approaches such as pulmonary rehabilitation, and pharmaco-
logical approaches the mainstay of which remains long-acting 
bronchodilators with or without inhaled corticosteroids and, in 
selected cases, prophylactic antibiotics. For patients remaining 
hypercapnic following a hospitalised exacerbation, domiciliary 
non-invasive ventilation significantly reduces the risk of rehos-
pitalisation (with an absolute risk reduction of 17% in a recent 
landmark study).103 Similar to strategies to better target exacer-
bation treatment, there is also now emerging evidence on how 
better to target exacerbation prevention interventions, including 
the optimal use of inhaled corticosteroids. Thus, while exac-
erbation prevention strategies are incompletely effective, the 
challenge here is rather selecting the right combination of inter-
ventions for the right patient at the right time, rather than the 
absence of effective prevention strategies.
ConCluSIonS
In 1878, R Douglas Powell advised that our management aims 
should be to save life and prevent further episodes of then acute 
and chronic bronchitis, now COPD. We still have a long way to 
go to achieve this. Exacerbations of COPD are still associated 
with significant mortality, morbidity, readmission and poor life 
quality. There have been no real advancements in routine care 
since the 1990s. There is considerable unmet need for novel 
strategies to identify, treat and prevent exacerbations, and a 
pressing need to better use existing therapies. This remains a 
major challenge. How do we move forward?
COPD as a disease concept has always raised the question of 
‘lumping or splitting’; is this one disease or many?104 Innovation 
in asthma care has provided a path which perhaps COPD should 
follow. Asthma phenotypes and now endotypes105 provide clin-
ically blurred but biologically distinct clusters with an emerging 
arsenal of treatments for those with the most difficult to manage 
symptoms. The concept of ‘treatable traits’ has gained consider-
able momentum in stable COPD,42 and perhaps now the same 
concept should be tested further in exacerbations. We are begin-
ning to see some differences in biological signals across exacer-
bation aetiologies and host responses. To build on this, we need 
to continue with more stratified studies of ECOPD, learning 
from the fruitful experience of focusing on those with an eosin-
ophilic signal, but this time using POC testing to characterise 
and test treatments in (eg) viral or pauci-inflammatory exacer-
bations. This will provide more information about aetiology, 
but to personalise treatment, this must be incorporated into a 
holistic understanding of the impact of the hosts comorbidity 
and immune responses.
From these data, we could build our ECOPD toolkit, which 
we hypothesise might include POC identification of bacterial or 
viral pathogen (ensuring that the correct antibacterial or viral 
therapy is used and thus reducing redundant therapy), blood 
biomarkers to identify or exclude an eosinophil (corticosteroid 
use or avoidance) or cardiac (acute coronary syndrome, heart 
failure) or neutrophilic treatment pathway and a measure of 
acuity and respiratory compromise. By exploring these ideas, we 
may be able to introduce a stratified approach to treatment and 
prevention, which might, finally, really impact on these debili-
tating and costly events, to the benefit of our patients.
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